A novel mouse model of inflammatory bowel disease links mammalian target of rapamycin-dependent hyperproliferation of colonic epithelium to inflammation-associated tumorigenesis

American Journal of Pathology

Volumn 176, Issue 2, 2010, Pages 952-967

  Deng, Lin ^a   Zhou, Jin Feng ^a   Sellers, Rani S ^b   Li, Jiu Feng ^b   Nguyen, Andrew V ^c   Wang, Yubao ^b   Orlofsky, Amos ^b   Liu, Qiang ^b   Hume, David A ^d   Pollard, Jeffrey W ^b   Augenlicht, Leonard ^a   Lin, Elaine Y ^a  

^a ALBERT EINSTEIN CANCER CENTER   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c CITY UNIVERSITY OF NEW YORK   (United States)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; STAT3 PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; COLITIS; COLON MUCOSA; COLORECTAL CANCER; ENTERITIS; EXPERIMENTAL MODEL; EXPERIMENTAL MOUSE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INFLAMMATION; INVASIVE CARCINOMA; LYMPHOID CELL; MACROPHAGE; MICROFLORA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; UPREGULATION; WESTERN BLOTTING;

EID: 76149117809     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.2353/ajpath.2010.090622     Document Type: Article

References (90)

1. Itzkowitz SH, Yio X: Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol 2004, 287:G7-G17
2. Strober W, Fuss I, Mannon P: The fundamental basis of inflammatory bowel disease. J Clin Invest 2007, 117:514-521
3. Wirtz S, Neurath MF: Mouse models of inflammatory bowel disease. Adv Drug Deliv Rev 2007, 59:1073-1083
4. Kawada M, Arihiro A, Mizoguchi E: Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. World J Gastroenterol 2007, 13:5581-5593
5. -/- mice: an overview. J Leukoc Biol 1997, 61:389-396
6. Marrakchi R, Moussa A, Ouerhani S, Bougatef K, Bouhaha R, Messai Y, Rouissi K, Khadimallah I, Khodjet-El-Khil H, Najar T, Benammar-Elgaaeid A: Interleukin 10 promoter region polymorphisms in inflammatory bowel disease in Tunisian population. Inflamm Res 2009, 58:155-160
7. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, Krawczak M, Vatn MH, Mathew CG, Schreiber S: Sequence variants in IL10. ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat Genet 2008, 40:1319-1323
8. Sanchez R, Levy E, Costea F, Sinnett D: IL-10 and TNF-α promoter haplotypes are associated with childhood Crohn's disease location. World J Gastroenterol 2009, 15:3776-3782
9. + TH1-like responses. J Clin Invest 1996, 98:1010-1020
10. Lang R: Tuning of macrophage responses by Stat3-inducing cytokines: molecular mechanisms and consequences in infection. Immunobiology 2005, 210:63-76
11. Alonzi T, Newton IP, Bryce PJ, Di Carlo E, Lattanzio G, Tripodi M, Musiani P, Poli V: Induced somatic inactivation of STAT3 in mice triggers the development of a fulminant form of enterocolitis. Cytokine 2004, 26:45-56
12. Takeda K, Clausen BE, Kaisho T, Tsujimura T, Terada N, Forster I, Akira S: Enhanced Th1 activity and development of chronic enterocolitis in mice devoid of Stat3 in macrophages and neutrophils. Immunity 1999, 10:39-49
13. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A: Interleukin-10 and the interleukin-10 receptor. Annu Rev Immunol 2001, 19:683-765
14. Takeda K, Kaisho T, Yoshida N, Takeda J, Kishimoto T, Akira S: Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice. J Immunol 1998, 161:4652-4660
15. Sasmono RT, Ehrnsperger A, Cronau SL, Ravasi T, Kandane R, Hickey MJ, Cook AD, Himes SR, Hamilton JA, Hume DA: Mouse neutrophilic granulocytes express mRNA encoding the macrophage colony-stimulating factor receptor (CSF-1R) as well as many other macrophage-specific transcripts and can transdifferentiate into macrophages in vitro in response to CSF-1. J Leukoc Biol 2007, 82:111-123
16. Sasmono RT, Oceandy D, Pollard JW, Tong W, Pavli P, Wainwright BJ, Ostrowski MC, Himes SR, Hume DA: A macrophage colony-stimulating factor receptor-green fluorescent protein transgene is expressed throughout the mononuclear phagocyte system of the mouse. Blood 2003, 101:1155-1163
17. Shimshek DR, Kim J, Hubner MR, Spergel DJ, Buchholz F, Casanova E, Stewart AF, Seeburg PH, Sprengel R: Codon-improved Cre recombinase (iCre) expression in the mouse. Genesis 2002, 32:19-26
18. Raz R, Lee CK, Cannizzaro LA, d'Eustachio P, Levy DE: Essential role of STAT3 for embryonic stem cell pluripotency. Proc Natl Acad Sci USA: 1999, 96:2846-2851
19. Lin EY, Orlofsky A, Berger MS, Prystowsky MB: Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol 1993, 151:1979-1988
20. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, Pitot HC, Halberg RB, Itzkowitz SH, Groden J, Coffey RJ: Pathology of mouse models of intestinal cancer: consensus report and recommendations. Gastroenterology 2003, 124:762-777
21. Xiao H, Gulen MF, Qin J, Yao J, Bulek K, Kish D, Altuntas CZ, Wald D, Ma C, Zhou H, Tuohy VK, Fairchild RL, de la Motte C, Cua D, Vallance BA, Li X: The Toll-interleukin-1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflammation, and tumorigenesis. Immunity 2007, 26:461-475
22. Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW: Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res 2006, 66:11238-11246
23. Odze R: Diagnostic problems and advances in inflammatory bowel disease. Mod Pathol 2003, 16:347-358
24. Blackstone MO, Riddell RH, Rogers BH, Levin B: Dysplasia-associated lesion or mass (DALM) detected by colonoscopy in long-standing ulcerative colitis: an indication for colectomy. Gastroenterology 1981, 80:366-374
25. Rautava S, Walker WA: Commensal bacteria and epithelial cross talk in the developing intestine. Curr Gastroenterol Rep 2007, 9:385-392
26. Baumgart DC: What's new in inflammatory bowel disease in 2008? World J Gastroenterol 2008, 14:329-330
27. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H: Notch/ γ-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963
28. Velcich A, Yang W, Heyer J, Fragale A, Nicholas C, Viani S, Kucherlapati R, Lipkin M, Yang K, Augenlicht L: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 2002, 295:1726-1729
29. Yang K, Popova NV, Yang WC, Lozonschi I, Tadesse S, Kent S, Bancroft L, Matise I, Cormier RT, Scherer SJ, Edelmann W, Lipkin M, Augenlicht L, Velcich A: Interaction of Muc2 and Apc on Wnt signaling and in intestinal tumorigenesis: potential role of chronic inflammation. Cancer Res 2008, 68:7313-7322
30. Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7:41-51
31. Mita AC, Mita MM, Nawrocki ST, Giles FJ: Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res 2008, 14:5000-5005
32. Altieri DC: Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008, 8:61-70
33. Petroulakis E, Mamane Y, Le Bacquer O, Shahbazian D, Sonenberg N: mTOR signaling: implications for cancer and anticancer therapy. Br J Cancer 2006, 94:195-199
34. Mamane Y, Petroulakis E, LeBacquer O, Sonenberg N: mTOR, translation initiation and cancer. Oncogene 2006, 25:6416-6422
35. Wen Z, Zhong Z, Darnell JE Jr: Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250
36. Yokogami K, Wakisaka S, Avruch J, Reeves SA: Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. Curr Biol 2000, 10:47-50
37. Podolsky DK: Inflammatory bowel disease. N Engl J Med 2002, 347:417-429
38. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, Xavier RJ, Libioulle C, Sandor C, Lathrop M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, Cardon LR, Anderson CA, Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, Mathew CG, Parkes M, Georges M, Daly MJ: Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008, 40:955-962
39. Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, Gwilliam R, Jacob J, Nimmo ER, Drummond H, Lees CW, Onnie CM, Hanson C, Blaszczyk K, Ravindrarajah R, Hunt S, Varma D, Hammond N, Lewis G, Attlesey H, Watkins N, Ouwehand W, Strachan D, McArdle W, Lewis CM, Lobo A, Sanderson J, Jewell DP, Deloukas P, Mansfield JC, Mathew CG, Satsangi J, Parkes M: Investigation of Crohn's disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 2009, 136:523-529
40. Sugimoto K: Role of STAT3 in inflammatory bowel disease. World J Gastroenterol 2008, 14:5110-5114
41. Fu XY: STAT3 in immune responses and inflammatory bowel diseases. Cell Res 2006, 16:214-219
42. Kobayashi M, Kweon MN, Kuwata H, Schreiber RD, Kiyono H, Takeda K, Akira S: Toll-like receptor-dependent production of IL-12p40 causes chronic enterocolitis in myeloid cell-specific Stat3-deficient mice. J Clin Invest 2003, 111:1297-1308
43. Coussens LM, Werb Z: Inflammation and cancer. Nature 2002, 420:860-867
44. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK: Role of cytokines in inflammatory bowel disease. World J Gastroenterol 2008, 14:4280-4288
45. Cross M, Mangelsdorf I, Wedel A, Renkawitz R: Mouse lysozyme M gene: isolation, characterization, and expression studies. Proc Natl Acad Sci USA: 1988, 85:6232-6236
46. Faust N, Varas F, Kelly LM, Heck S, Graf T: Insertion of enhanced green fluorescent protein into the lysozyme gene creates mice with green fluorescent granulocytes and macrophages. Blood 2000, 96:719-726
47. Goren I, Allmann N, Yogev N, Schurmann C, Linke A, Holdener M, Waisman A, Pfeilschifter J, Frank S: A transgenic mouse model of inducible macrophage depletion: effects of diphtheria toxin-driven lysozyme M-specific cell lineage ablation on wound inflammatory, angiogenic, and contractive processes. Am J Pathol 2009, 175:132-147
48. Musso A, Dentelli P, Carlino A, Chiusa L, Repici A, Sturm A, Fiocchi C, Rizzetto M, Pegoraro L, Sategna-Guidetti C, Brizzi MF: Signal transducers and activators of transcription 3 signaling pathway: an essential mediator of inflammatory bowel disease and other forms of intestinal inflammation. Inflamm Bowel Dis 2005, 11:91-98
49. Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, Denson LA: Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm Bowel Dis 2008, 14:446-457
50. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF: Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med 2000, 6:583-588
51. Maloy KJ, Kullberg MC: IL-23 and Th17 cytokines in intestinal homeostasis. Mucosal Immunol 2008, 1:339-349
52. Ouyang W, Kolls JK, Zheng Y: The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467
53. Laurence A, O'Shea JJ, Watford WT: Interleukin-22: a sheep in wolf's clothing. Nat Med 2008, 14:247-249
54. Murray PJ: The JAK-STAT signaling pathway: input and output integration. J Immunol 2007, 178:2623-2629
55. Burstein E, Fearon ER: Colitis and cancer: a tale of inflammatory cells and their cytokines. J Clin Invest 2008, 118:464-467
56. Xie J, Itzkowitz SH: Cancer in inflammatory bowel disease. World J Gastroenterol 2008, 14:378-389
57. Chan EP, Lichtenstein GR: Chemoprevention: risk reduction with medical therapy of inflammatory bowel disease. Gastroenterol Clin North Am 2006, 35:675-712
58. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL: Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989, 96:795-803
59. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R: A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702
60. Boirivant M, Fuss IJ, Chu A, Strober W: Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J Exp Med 1998, 188:1929-1939
61. Mulcahy HE, O'Donoghue D: Nonsteroidal anti-inflammatory drugs and their colonic effects: more interesting than irritating?. Eur J Gastroenterol Hepatol 2002, 14:1177-1178
62. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA: The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000, 60:5040-5044
63. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M: Inhibition of NF-κB in cancer cells converts inflammation- induced tumor growth mediated by TNFα to TRAIL-mediated tumor regression. Cancer Cell 2004, 6:297-305
64. Abou-Ghazal M, Yang DS, Qiao W, Reina-Ortiz C, Wei J, Kong LY, Fuller GN, Hiraoka N, Priebe W, Sawaya R, Heimberger AB: The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res 2008, 14:8228-8235
65. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA: Inflammation and liver cancer: new molecular links. Ann NY Acad Sci 2009, 1155:206-221
66. Starska K, Brys M, Forma E, Glowacka E, Lewy-Trenda I, Stasikowska O, Krajewska WM, Lukomski M: Impact of EGFR immunoexpression on STAT3 activation and association with proinflammatory/regulatory cytokine pattern in laryngeal squamous cell carcinoma. Oncol Rep 2009, 21:539-548
67. Corvinus FM, Orth C, Moriggl R, Tsareva SA, Wagner S, Pfitzner EB, Baus D, Kaufmann R, Huber LA, Zatloukal K, Beug H, Ohlschlager P, Schutz A, Halbhuber KJ, Friedrich K: Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia 2005, 7:545-555
68. Atreya R, Neurath MF: Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin Rev Allergy Immunol 2005, 28:187-196
69. Couper KN, Blount DG, Riley EM: IL-10: the master regulator of immunity to infection. J Immunol 2008, 180:5771-5777
70. Ouyang W, Valdez P: IL-22 in mucosal immunity. Mucosal Immunol 2008, 1:335-338
71. Hulit J, Wang C, Li Z, Albanese C, Rao M, Di Vizio D, Shah S, Byers SW, Mahmood R, Augenlicht LH, Russell R, Pestell RG: Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 2004, 24:7598-7611
72. Adams JM, Cory S: The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007, 26:1324-1337
73. Alao JP: The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention. Mol Cancer 2007, 6:24
74. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, Vallabhapurapu S, Scheller J, Rose-John S, Cheroutre H, Eckmann L, Karin M: IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 2009, 15:103-113
75. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T, Nebelsiek T, Lundgren-May T, Canli O, Schwitalla S, Matthews V, Schmid RM, Kirchner T, Arkan MC, Ernst M, Greten FR: gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102
76. He M, Young CY: New approaches to target the androgen receptor and STAT3 for prostate cancer treatments. Mini Rev Med Chem 2009, 9:395-400
77. Heimberger AB, Priebe W: Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat CNS Drug Discov 2008, 3:179-188
78. Costantino L, Barlocco D: STAT 3 as a target for cancer drug discovery. Curr Med Chem 2008, 15:834-843
79. Dann SG, Selvaraj A, Thomas G: mTOR Complex1-S6K1 signaling: at the crossroads of obesity, diabetes and cancer. Trends Mol Med 2007, 13:252-259
80. Le Tourneau C, Faivre S, Serova M, Raymond E: mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work? Br J Cancer 2008, 99:1197-1203
81. Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 2006, 5:671-688
82. Memmott RM, Dennis PA: Akt-dependent and -independent mechanisms of mTOR regulation in cancer. Cell Signal 2009, 21:656-664
83. Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP: Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell 2005, 121:179-193
84. Waetzig GH, Seegert D, Rosenstiel P, Nikolaus S, Schreiber S: p38 mitogen-activated protein kinase is activated and linked to TNF-α signaling in inflammatory bowel disease. J Immunol 2002, 168:5342-5351
85. Wang B, Xiao Z, Chen B, Han J, Gao Y, Zhang J, Zhao W, Wang X, Dai J: Nogo-66 promotes the differentiation of neural progenitors into astroglial lineage cells through mTOR-STAT3 pathway. PLoS ONE 2008, 3:e1856
86. Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J, Margolick JB, Liotta LA, Petricoin E, 3rd, Zhang Y: Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA: 2007, 104:16158-16163
87. Riemenschneider MJ, Betensky RA, Pasedag SM, Louis DN: AKT activation in human glioblastomas enhances proliferation via TSC2 and S6 kinase signaling. Cancer Res 2006, 66:5618-5623
88. Kim JH, Kim JE, Liu HY, Cao W, Chen J: Regulation of interleukin-6- induced hepatic insulin resistance by mammalian target of rapamycin through the STAT3-SOCS3 pathway. J Biol Chem 2008, 283:708-715
89. Sands BE: Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007, 42:16-25
90. Xavier RJ, Podolsky DK: Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007, 448:427-434